Oncotelic Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-13.8M | $-13.7M | $-13.7M | $-12.6M | $-8.3M | $-8.1M | $-9.7M | $-23.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $9.0K | $19.0K | $20.0K | $16.0K | $12.0K | $29.0K | $53.0K | $96.0K |
| Amortization | — | — | — | $1.5M | $7.8K | $8.1K | — | — |
| Stock-Based Compensation | $835.0K | $804.0K | $806.0K | $414.0K | $679.0K | $511.0K | $851.0K | $952.0K |
| Net Cash from Operating Activities | $-10.9M | $-15.2M | $-11.9M | $-12.2M | $-7.0M | $-8.3M | $-11.8M | $-20.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $13.0K | $17.0K | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $8.5M | — | — | — | $-35.0K | $-8.0K | — | $3.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | — | — | $9.1M | $3.3M | $17.2M | $11.1M |
| Net Change in Cash | $-2.4M | $-23.8M | $-2.7M | $23.0M | $2.1M | $-5.0M | $5.4M | $-9.3M |
| Free Cash Flow | — | — | $-11.9M | $-12.2M | — | — | — | — |